American Journal of Pharmacological Sciences
ISSN (Print): 2327-6711 ISSN (Online): 2327-672X Website: http://www.sciepub.com/journal/ajps Editor-in-chief: Srinivas NAMMI
Open Access
Journal Browser
Go
American Journal of Pharmacological Sciences. 2016, 4(3), 39-45
DOI: 10.12691/ajps-4-3-3
Open AccessArticle

Losartan versus Enalapril in the Protection of the Gastric Mucosa against Aspirin-Induced Gastric Mucosal Injury in Rats

Mahmoud H. Abdel-Rahim1, Sanaa A. Ahmed2, and Hytham M. Abdel-Latif2

1Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt

2Department of Pharmacology, Faculty of Medicine, Sohag University, Sohag, Egypt

Pub. Date: July 11, 2016

Cite this paper:
Mahmoud H. Abdel-Rahim, Sanaa A. Ahmed and Hytham M. Abdel-Latif. Losartan versus Enalapril in the Protection of the Gastric Mucosa against Aspirin-Induced Gastric Mucosal Injury in Rats. American Journal of Pharmacological Sciences. 2016; 4(3):39-45. doi: 10.12691/ajps-4-3-3

Abstract

Different mechanisms have been suggested for the development of nonsteroidal anti-inflammatory drugs (NSAIDs) induced gastropathy. Angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) have been suggested to have gastroprotective effects, sothe present work aims to elucidate the protective effect of the renin-angiotensin system (RAS) inhibitors through their effect on prostaglandins (PGs) and oxidative stress against peptic ulcer induced by aspirin in rats and to compare the efficacy of ACEIs and ARBs in the treatment of peptic ulcer. Thirty-six adult male Wistar rats weighing 180-200 g were randomly divided into 6 groups, 6 animals each. Groups 1, 2, and 3 were received saline (normal control), losartan (3mg/kg/day) and enalapril (10 mg/kg/day) i.p respectively for 4 weeks. Groups 4, 5, and 6 were pretreated with saline (aspirin group), losartan (3mg/kg/day) and enalapril (10 mg/kg/day) i.p respectively for 4 weeks duration. On 29th day, rats of group 4, 5 and 6 were submitted to gastric ulcer by single oral administration of 300 mg/kg aspirin then animals of all groups were sacrificed, stomachs were excised for gross and microscopic examination and determination of the mucosal levels of prostaglandin E2 (PGE2), superoxide dismutase (SOD), nitric oxide (NO) and catalase (CAT).Treatment of rats with aspirin produced a significant decrease in gastric PGE2, SOD, NO, and CAT levels and produced deep gastric ulcer compared to normal control group. Pretreatment of rats with losartan or enalapril decreased the aspirin-induced alterations in gastric PGE2.SOD and NO levels, but only losartan caused a significant increase in CAT activity while enalapril caused an insignificant increase. Also, pretreatment with losartan or enalapril ameliorated the severe deep gastric ulcer induced by aspirin to shallow erosions and inflamed gastric mucosa compared to changes in the aspirin group.In conclusions, the prophylactic use of losartan and enalapril ameliorated aspirin-induced gastric ulcer, but losartan has better influence as it has an additional effect on CAT.

Keywords:
losartan enalapril aspirin gastric ulcer PGE2 SOD catalase

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Carl-McGrath, S., Grntzdrffer, I. and Lendeckel, U. “Angiotensin II-generating enzymes, angiotensin-converting enzyme and mast cell chymase (CMA1), in gastric inflammation may be regulated by H. pylori and associated cytokines”. J. Pathol, 41(5), 419-427. 2009.
 
[2]  Griendling, K., Lassegue, B. and Alexander, R. “Angiotensin receptors and their therapeutic implications”. Ann Rev Pharmacol Toxicol, 36(1), 281-306. 1996.
 
[3]  Heinemann A, Sattler V and Jocic M. “Effect of angiotensin II and telmisartan, an angiotensin I receptor antagonist, on gastric mucosal blood flow”. Aliment PharmacolTher13: 347-355. 1999.
 
[4]  Touyz, R. “Reactive oxygen species and angiotensin II signaling in vascular cells: implications in cardiovascular disease”. Braz J Med Biol Res, 37(8), 1263-1273. 2004.
 
[5]  Tandon, R., Khanna, H. and Dorababu, M. “Oxidative stress and antioxidants status in peptic ulcer and gastric carcinoma”. Indian J. Physiol. Pharmacol. 48, pp. 115-118. 2004.
 
[6]  Maiden, L. “Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy”. J. Gastroenterol., 44(19), 64-71. 2009.
 
[7]  Wallace, J. “How do NSAIDs cause ulcer disease?” Clin Gastroenterol, 14(1), 147-159. 2000.
 
[8]  Shiotani, A., Sakakibara, T. and Yamanaka, Y. “Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin”. J. Gastroenterol. 44:126-131. 2009.
 
[9]  Nakagiri, A., Sunamoto, M. and Murakami, M. “Angiotensin AT1 receptor blockers suppress ischemia/reperfusion-induced gastric injury in rats”. Inflammopharmacol.; 15(4):171-174. 2007.
 
[10]  Baluchnejadmojarad, T., Roghani, M. and Imani, A. “Protective effect of enalapril on vascular reactivity of the rat aorta”. Vasc Pharmacol., 40: 301-307. 2004.
 
[11]  Fesharaki, M., Nasimi, A. and Mokhatari, S. “Reactive oxygen metabolites and antioxidative defenses in aspirin-induced gastric damage in rats: Gastroprotection by vitamin E”. J. Pathophysiol; 13 (4): 237- 243. 2006.
 
[12]  Fernández, N., Alonso, S., Valera, I. and Vigo, A. “Mannose-containing molecular patterns are strong inducers of cyclooxygenase-2 expression and prostaglandin E2 production in human macrophages”. J Immunol., 174: 8154-8162. 2005.
 
[13]  Nishikimi, M., Appaji, N. and Yagi, K. “The occurrence of superoxide anion in the reaction of reduced phenazinemethosulfate and molecular oxygen”. Biochem. Biophys. Res. Commun., 46, 849-854. 1972.
 
[14]  Aebi, H. “Catalase in vitro”. Methods Enzymol., 105, 121-126. 1984.
 
[15]  Montgomery, H. and Dymock, J. “The determination of nitrite in water”. Analyst. 86: 414-416. 1961.
 
[16]  Shiotani, A., Nishi, R. and Yamanaka, Y. “Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low-dose aspirin”. Dig Dis Sci., 56 (2), 465-471. 2011.
 
[17]  Brzozowski, T., Konturek, P. and Konturek, S. “Role of prostaglandins in gastroprotection and gastric adaptation”. J. Physiol. Pharmacol., 56, 33-39. 2005.
 
[18]  Lichtenberger, L., Romero, J. and Dial, E. “Surface phospholipids in gastric injury and protection when a selective cyclooxygenase inhibitor (Coxib) is used in combination with aspirin”. Br J Pharmacol., 150 (7), 913-919. 2007.
 
[19]  Wang, G., Huang, G. and Yin, G “Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats”. Cell PhysiolBiochem, 20(1-4), 205-212. . 2007.
 
[20]  Morsy, M., Ashour, O. and Amin, E. “Gastroprotective effects of telmisartan on experimentally-induced gastric ulcers in rats”. Int J Pharmaceut Sci., 64(9), 590-594. 2009.
 
[21]  Matloub, S. “Captopril versus enalapril in the protection of the gastric mucosa against NSAID induced gastric mucosal injury in rats”. J Fac Med Baghdad, 53(2), 236-240. 2011.
 
[22]  Salvemini, D., Settle, S. and Masferrer, J. “Regulation of prostaglandin production by nitric oxide; and in vivo analysis”. Br J Pharmacol., 114(6), 1171-1178. 1995.
 
[23]  Sautebin, L., Ialenti, A. and Ianaro, A. “Modulation by nitric oxide of prostaglandin biosynthesis in the rat”. Br. J. Pharmacol., 114(2), 323-328. 1995.
 
[24]  Kim, H. and Kim, K. “Effect of nitric oxide on hydrogen peroxide-induced damage in isolated rabbit gastric glands”. Pharmacology 57, 323-330. 1998.
 
[25]  Tanaka, J., Yuda, Y. and Inouye, S. “The role of nitric oxide in the gastric acid secretion induced by ischemia-reperfusion in the pylorus-ligated rat”. Eur. J. Pharmacol. 424, 69-74. 2001.
 
[26]  Whittle, B., Lopez-Belmonte, J. and Moncada, S. “Regulation of gastric mucosal integrity by endogenous nitric oxide: Interactions with prostanoids and sensory neuropeptides in the rat”. Br. J. Pharmacol. 99, 607-611. 1990.
 
[27]  Tripp, M. and Tepperman, B. “Effect of nitric oxide on integrity, blood flow and cyclic GMP levels in the rat gastric mucosa”. Br. J. Pharmacol. 115(2), 344-348. 1995.
 
[28]  Donmez, G., Derici, U. and Erbas, D. “The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension”. Jpn JPhysiol, 52(5), 435-440. 2002.
 
[29]  Fridovich, I. “Biological effects of superoxide radical”. Arch. Biochem. Biophy.; 247: 1-11. 1986.
 
[30]  Ito, N., Hirose, M. and Imaida, K. “Antioxidants: Carcinogenic and chemopreventive properties”. Adv. Cancer. Res., 53: 247-302. 1996.
 
[31]  Pohle, T., Brzozowski, T., Becker, J. andVan der Voort, I. “Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C”. Aliment Pharmacol Ther. May; 15(5):677-87. 2001.
 
[32]  Ajaikumar, K., Asheef, M. and Babu, B. “The inhibition of gastric mucosal injury by Punicagranatum L. (pomegranate) metabolic extract” J Ethnopharmacol., 96(1).171-176.2005.
 
[33]  Héctor A. and Peña, C. “Effects of angiotensin pomegranate) methanolic extract”. J. Ethnopharmacol., 96(1). 171-176. 2005.II type 1 receptor blockade on the oxidative stress in spontaneously hypertensive rat tissues”. RegulPept., 128(1): 1-5. 2005.
 
[34]  De Cavanagh, E., Inserra, F. and Ferder, L. “Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver”. FEBS Lett, 361(1), 22-24. 1995.
 
[35]  Khaper, N. and Singal, P. “Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats”. J Am CollCardiol., 37(5), 1461-1466. 2001.
 
[36]  Santos, E., de Picoli Souza, K. and da Silva, E. “Long-term treatment with ACE inhibitor enalapril decreases body weight gain and increase life span in rats”. Biochem Pharmacol, 78(8), 951-958. 2009.
 
[37]  Kappert, K., Tsuprykov, O. and Kaufmann, J. “Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPAR activation”. Hypertension; 54: 738-743. 2009.
 
[38]  Schupp, M., Lee, L. and Frost, N. “Regulation of Peroxisome Proliferator Activated Receptor Activity by Losartan Metabolites”. Hypertension, 47(3), 586-589.2006.